Physician profile
Emily Lee
NPI 1750856712
$709.47
in general payments reported to CMS, 2019-2025
18 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $108 · 2023: $156 · 2024: $144 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $157.30 | 2021-2025 | Mounjaro, Jardiance |
| Idorsia Pharmaceuticals US INC | $81.48 | 2023-2024 | Quviviq |
| Novo Nordisk INC | $71.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $53.92 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $40.64 | 2022-2025 | |
| Genentech USA, INC. | $38.66 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.44 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $31.84 | 2024-2025 | Breztri, Airsupra |
| Pfizer INC. | $26.44 | 2022-2023 | |
| Boston Scientific Corporation | $25.62 | 2025 | Spectra Wavewriter |
| Biohaven Pharmaceuticals, INC. | $22.67 | 2021 | |
| Dexcom, INC. | $21.39 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.37 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.53 | 2021 | |
| Merck Sharp & Dohme LLC | $18.80 | 2024 | Capvaxive |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.74 | 2023 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $13.98 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.